Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
estradiol + estriol, commonly referred to as **Biest**, is a combination of two bioidentical estrogens used primarily in bioidentical hormone replacement therapy (BHRT). Estradiol (E2) is the most potent and abundant endogenous estrogen in premenopausal women, while estriol (E3) is a weaker estrogen metabolite that is produced in high quantities during pregnancy. In the Biest formulation, these two hormones are typically combined in specific ratios—most commonly an 80:20 or 50:50 ratio of estriol to estradiol. The rationale behind this combination is to provide the symptomatic relief associated with estradiol while potentially mitigating its stimulatory effects on the breast and endometrium through the inclusion of the weaker, more selective estriol. Biest is predominantly prepared by compounding pharmacies and is most frequently administered as a transdermal cream or gel to avoid first-pass hepatic metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estradiol + estriol.